Cowen & Co. reaffirmed its Buy rating on Johnson & Johnson, boosting the firm’s 12-month price target from $222 to $250. This upward revision reflects Cowen’s confidence in J&J’s diverse pharmaceutical and medical-devices pipeline, including late-stage oncology therapies poised for approvals in the next 12 months. The raise from $222 represents a 12.6% increase in implied upside, underscoring analysts’ expectation that J&J’s strategic investments and innovation cadence will drive share appreciation over the coming year.

Zacks Investment Research has identified Johnson & Johnson as a leading candidate to exceed consensus earnings estimates, based on its proprietary Earnings ESP tool. The model currently signals a positive surprise probability, fueled by stronger-than-anticipated sales in immunology and oncology segments. Zacks notes that analyst revisions over the past month have trended upward, a typical precursor to a quarterly beat, suggesting that investors should prepare for robust Q1 results.

Johnson & Johnson commands a market capitalization of approximately $530 billion, ranking it among the top three healthcare companies globally. In the past week, average daily trading volume exceeded 2.1 million shares, indicating active participation by institutional and retail investors. Over the past 12 months, the stock has traded in a range where its highest annual level equates to a 13% premium over its lowest point, reflecting sustained demand through market cycles.

With its consumer-health spin-off now independent, J&J remains focused on pharmaceuticals and medical technologies, sectors that generated combined revenues of $94.2 billion last year. The company allocated $14.7 billion to R&D in the most recent fiscal year and completed $17.7 billion in acquisitions, including neuroscience and oncology targets. These commitments, along with a five-year dividend growth streak exceeding 6% annually, reinforce J&J’s profile as a core holding for income-oriented and quality-focused portfolios.